• Ruxolitinib

    Ruxolitinib

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Ruxolitinib Myelofibrosis Novartis Jul. 6, 2024
  • Crisaborole

    Crisaborole

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Crisaborole Atopic Dermatitis and Eczema Pfizer Jun. 11, 2026 
  • Relugolix

    Relugolix

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Relugolix Prostatic cancer Takeda and ASKA Jan. 24, 2024
  • Vericiguat

    Vericiguat

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Vericiguat Heart failure Bayer and MSD May. 24, 2031
  • Abrocitinib

    Abrocitinib

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Abrocitinib Atopic Dermatitis Pfizer Feb.11, 2034
  • Rimegepant

    Rimegepant

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Rimegepant Migraine headache Biohaven Feb. 22, 2031

     

  • Elagolix 834153-87-6

    Elagolix 834153-87-6

    API’s Name Indication Specification US DMF EU DMF CEP
    Elagolix CAS: 834153-87-6 Endometriosis In-House      
  • Relugolix 737789-87-6

    Relugolix 737789-87-6

    API’s Name Indication Specification US DMF EU DMF CEP
    Ribociclib CAS: 737789-87-6 Antineoplastic In-House      
  • Venetoclax 1257044-40-8

    Venetoclax 1257044-40-8

    API’s Name Indication Innovator Patent Expiry Date(The U.S)
    Venetoclax 1257044-40-8 CLL Abbvie Jun.27,2031
  • Velpatasvir(PVP)

    Velpatasvir(PVP)

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Velpatasvir(PVP) HCV In-House    
  • Thalidomide

    Thalidomide

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Thalidomide Oncology drug USP/EP      
  • Ticagrelor

    Ticagrelor

    API’s Name Indication Specification US DMF  EU DMF  CEP
    Ticagrelor Anticoagulant In-House 28984  
1234 Next > >> Page 1 / 4